De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ono Pharmaceutical Toekomstige groei

Future criteriumcontroles 0/6

De winst van Ono Pharmaceutical zal naar verwachting dalen met 10.6% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 0.7% per jaar. De winst per aandeel zal naar verwachting dalen met 10.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 8.4% zijn.

Belangrijke informatie

-10.6%

Groei van de winst

-10.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	13.8%
Inkomstengroei	0.7%
Toekomstig rendement op eigen vermogen	8.4%
Dekking van analisten	Good
Laatst bijgewerkt	24 Sep 2024

Recente toekomstige groei-updates

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

Recent updates

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Aug 25

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 04

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Jun 24

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Mar 04

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Feb 27

Winst- en omzetgroeiprognoses

TSE:4528 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	521,546	80,479	83,004	118,887	11
3/31/2026	513,881	77,356	68,132	104,708	12
3/31/2025	484,079	75,702	11,800	99,189	12
6/30/2024	500,331	120,953	105,249	121,111	N/A
3/31/2024	502,672	127,977	89,831	110,660	N/A
12/31/2023	498,070	127,611	91,301	106,044	N/A
9/30/2023	489,199	124,875	97,371	115,354	N/A
6/30/2023	460,481	115,064	98,429	116,894	N/A
3/31/2023	447,187	112,723	145,113	159,610	N/A
12/31/2022	428,951	111,555	137,391	149,495	N/A
9/30/2022	403,985	96,568	93,387	102,437	N/A
6/30/2022	380,720	85,922	78,395	88,151	N/A
3/31/2022	361,361	80,519	49,552	61,829	N/A
12/31/2021	345,781	73,558	38,233	53,343	N/A
9/30/2021	332,887	81,866	60,412	83,032	N/A
6/30/2021	321,734	78,003	47,401	70,321	N/A
3/31/2021	309,284	75,425	53,684	73,977	N/A
12/31/2020	302,054	74,364	53,088	72,011	N/A
9/30/2020	293,886	66,737	55,742	70,596	N/A
6/30/2020	293,351	64,870	58,824	78,232	N/A
3/31/2020	292,420	59,704	51,712	74,157	N/A
12/31/2019	290,736	60,233	43,202	73,947	N/A
9/30/2019	293,247	55,510	38,797	66,058	N/A
6/30/2019	291,374	52,633	32,152	58,850	N/A
3/31/2019	288,634	51,539	37,172	66,774	N/A
12/31/2018	284,463	51,978	42,500	67,269	N/A
9/30/2018	284,785	57,919	29,645	61,700	N/A
6/30/2018	272,165	53,746	16,591	48,716	N/A
3/31/2018	261,836	50,284	N/A	15,727	N/A
12/31/2017	256,522	54,760	N/A	28,754	N/A
9/30/2017	248,517	53,884	N/A	40,205	N/A
6/30/2017	246,953	53,887	N/A	53,650	N/A
3/31/2017	244,797	55,793	N/A	74,450	N/A
12/31/2016	236,710	48,270	N/A	44,743	N/A
9/30/2016	207,707	36,225	N/A	32,972	N/A
6/30/2016	183,345	29,206	N/A	16,805	N/A
3/31/2016	160,284	24,979	N/A	12,842	N/A
12/31/2015	140,927	16,449	N/A	29,716	N/A
9/30/2015	143,697	21,568	N/A	31,169	N/A
6/30/2015	139,663	19,521	N/A	30,488	N/A
3/31/2015	135,775	12,976	N/A	31,579	N/A
12/31/2014	137,592	17,663	N/A	N/A	N/A
9/30/2014	133,926	13,474	N/A	19,681	N/A
6/30/2014	137,146	16,787	N/A	N/A	N/A
3/31/2014	143,247	20,350	N/A	28,422	N/A
12/31/2013	145,946	21,574	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van 4528 zal naar verwachting de komende 3 jaar dalen ( -10.6% per jaar).

Winst versus markt: De winst van 4528 zal naar verwachting de komende 3 jaar dalen ( -10.6% per jaar).

Hoge groeiwinsten: De winst van 4528 zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van 4528 ( 0.7% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 4528 ( 0.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 4528 zal naar verwachting over 3 jaar laag zijn ( 8.4 %).

Ono Pharmaceutical Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates fall by 23%

Price target decreased by 10% to JP¥2,336

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Price target increased by 7.4% to JP¥2,935

Recent updates

Upcoming dividend of JP¥40.00 per share

We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt

Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Final dividend of JP¥40.00 announced

Consensus EPS estimates fall by 23%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings

Price target decreased by 10% to JP¥2,336

Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others.

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 10%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024

ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL

Upcoming dividend of JP¥40.00 per share

Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00

Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

Price target increased by 7.4% to JP¥2,935

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥40.00 per share at 2.8% yield

Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million.

Now 20% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Now 21% undervalued after recent price drop

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥33.00 per share at 2.4% yield

Price target decreased by 7.4% to JP¥3,292

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥33.00 per share

Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued

Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings: EPS misses analyst expectations

Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Consensus EPS estimates fall by 11%

Now 21% undervalued

Less than half of directors are independent

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million.

Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021)

Upcoming dividend of JP¥28.00 per share

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020)

Upcoming dividend of JP¥22.50 per share

Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

New 90-day low: JP¥3,020

Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020)